Genetic fine-mapping studies in breast cancer suggest that cis-regulatory risk variants may disrupt DNA binding affinities of TFs, particularly for known master regulators FOXA1 and ESR1, altering the regulation of gene expression and affecting breast cancer risk1–7. This evidence concerns the gene FOXA1 and breast carcinoma.